FDA Restricts Clinical Trial Review Board Over Safety

Law360, New York (August 27, 2009, 1:57 PM EDT) -- Institutional review board Coast IRB LLC agreed Tuesday to stop reviewing new research studies regulated by the U.S Food and Drug Administration, after the agency expressed serious concerns over whether the company could protect human subjects participating in the clinical trials it oversees.

After receiving a warning letter from the FDA, Coast voluntarily stopped taking new studies and halted the enrollment of new subjects in the studies it currently reviews.

The FDA's actions follow on the heels of a recent undercover operation conducted by the U.S....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.